Evidence map›Paper›PMID 37067556›Full record

ArticleAnnals of hematology2023

Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Muzaffer Keklik, Burak Deveci, Serhat Celik, Kemal Deniz, Zeynep Burcin Gonen, Gokmen Zararsiz, Rabin Saba, Gulsah Akyol, Yusuf Ozkul, Leylagul Kaynar and 4 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. [Research advances in mesenchymal stem cell therapy for graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Muzaffer KeklikDepartment of Hematology, Erciyes University, Kayseri, Turkey. muzafferkeklik@yahoo.com.ORCID http://orcid.org/0000-0002-6426-5249
Burak DeveciHematology and Stem Cell Transplantation Unit, Medstar Antalya Hospital, Antalya, Turkey.
Serhat CelikDepartment of Hematology, Kirikkale University, Kirikkale, Turkey.
Kemal DenizDepartment of Pathology, Erciyes University, Kayseri, Turkey.
Zeynep Burcin GonenDepartment of Oral and Maxillofacial Surgery, Faculty of Dentistry and Genome - Stem Cell Center, Erciyes University, Kayseri, Turkey.
Gokmen ZararsizDepartment of Biostatistics, Faculty of Medicine, Erciyes University and Turcosa Analytics Solutions Ltd. Co, Erciyes Teknopark, Kayseri, Turkey.
Rabin SabaInfectious Disease Unit, Medstar Antalya Hospital, Antalya, Turkey.
Gulsah AkyolDepartment of Hematology, Erciyes University, Kayseri, Turkey.
Yusuf OzkulDepartment of Medical Genetics, Medical School, Erciyes University, Kayseri, Turkey.
Leylagul KaynarDepartment of Hematology, Erciyes University, Kayseri, Turkey.
Ertugrul KeklikDepartment of Physiology, Kayseri City Hospital, Kayseri, Turkey.
Ali UnalDepartment of Hematology, Erciyes University, Kayseri, Turkey.
Mustafa CetinHematology and Stem Cell Transplantation Unit, Medstar Antalya Hospital, Antalya, Turkey.
Olcay Y JonesDivision of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Erciyes University · TRAntalya IVF · TRGeorge Washington University · USIstanbul Medipol University · TRKayseri Eğitim ve Araştırma Hastanesi · TRKırıkkale University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graft versus host disease (GvHD) remains a significant risk for mortality and morbidity following allogeneic hematopoietic stem cell transplantation (HSCT). A growing literature supports successful applications of mesenchymal stromal cells (MSCs) for the treatment of steroid-refractory acute GvHD (aGvHD). However, there is limited knowledge about the effects of MSC treatment on late-acute GvHD (late aGvHD). In this article, we present our multicenter study on the safety and efficacy of MSC therapy for patients with steroid-refractory late aGvHD in comparison to those with aGvHD. The outcome measures include non-relapse mortality (NRM) and survival probability over a 2-year follow-up. The study includes a total of 76 patients with grades III-IV aGvHD (n = 46) or late aGvHD (n = 30), who had been treated with at least two lines of steroid-containing immunosuppressive therapy. Patients received weekly adipose or umbilical cord-derived MSC infusions at a dose of median 1.55 (ranging from 0.84 to 2.56) × 10

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAcute DiseaseChronic DiseaseHumansNeoplasm Recurrence, LocalSteroidsSteroidsAllogeneic hematopoietic stem cell transplantationGraft-versus-host diseaseMesenchymal stromal cells

Identifiers

PMID37067556
OpenAlexW4366084342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.